Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices

Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, M. Catherine Pietanza, Bilal Piperdi, Thomas Burke

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices'. Together they form a unique fingerprint.

Medicine & Life Sciences